NPS Pharmaceuticals, Inc. NPSP, a biopharmaceutical company
pioneering and delivering therapies that transform the lives of patients
with rare diseases worldwide, today reported that results from the
company's STEPS 2 study of GATTEX® (teduglutide) in patients
with Short Bowel Syndrome (SBS) were accepted for presentation at the
American College of Gastroenterology (ACG) Annual Scientific Meeting and
Postgraduate Course in San Diego, California, October 11-16, 2013. STEPS
2 was a two-year open-label extension study that involved 88 adult SBS
patients with short bowel syndrome. The abstract entitled, “Long-term
Safety and Efficacy of Teduglutide for the Treatment of Intestinal
Failure Associated with Short Bowel Syndrome: Final Results of the
Steps-2 Study, a 2-year, Multicenter, Open-label Clinical Trial” by
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in